Mirtazapine, like all antidepressants can cause a variety of severe symptoms when withdrawing due to a state of Serotonin dysregulation. This is particularly true with a sudden withdrawal from Mirtazapine and the symptoms can be minimized by tapering off Mirtazapine gradually.  Yet many find even a small dose reduction causes symptoms that interfere with every aspect of life. This is why we implement both slowly tapering off Mirtazapine with a proven holistic approach to easing Mirtazapine withdrawal. Over the last 17 years our methodology has been implemented worldwide and can provide the best chance of success to get off Mirtazapine.*
Below is information about Mirtazapine, Mirtazapine withdrawal, and getting off Mirtazapine naturally.
WHAT IS MIRTAZAPINE WITHDRAWAL LIKE?
MIRTAZAPINE WITHDRAWAL HELP - GETTING OFF NATURALLY
At Point of Return, we have learned what helps with Mirtazapine withdrawal. The Point of Return Mirtazapine withdrawal program is a proven holistic approach that allows you to step down on Mirtazapine while minimizing Mirtazapine withdrawal symptoms with calming supplements that will not interact yet provide the needed relief. Your Mirtazapine weaning program is done under the guidance of Our Team, Your Physician and Pharmacist which allows you to begin tapering off Mirtazapine at small rates not produced by the pharmaceutical companies. Our Pre-Taper is for Mirtazapine Symptom Relief - You will not wean Mirtazapine until you feel better. This is where our advanced nutraceuticals are critical due to the unique demands placed on the body and nervous system by the antidepressant. Point of Return provides healthy, proven, Drug-Free Strategies to help ease Mirtazapine withdrawal symptoms while supporting your well being.
Each program is individualized based on your particular situation. We email an assessment when you order the program which allows us to uniquely customize each program to tailor needs. Factors we assess are age; length of time on the Mirtazapine; other medications; health challenges; life stressors and stress levels; goals and drug/drug, drug/herb, drug/vitamin interactions. No need to go through Mirtazapine withdrawal alone, work with our Prescription Drug Experts.*
MIRTAZAPINE WITHDRAWAL SYMPTOMS MAY INCLUDE
- balance issues
- blurred vision
- brain zaps
- concentration impairment
- crying spells
- electric shock sensations
- flu-like symptoms
- highly emotional
- impaired speech
- jumpy nerves
- lack of coordination
- migraine headaches / increased headaches
- over-reacting to situations
- repetitive thoughts or songs
- sensory & sleep disturbances
- severe internal restlessness (akathisia)
- stomach cramps
- tremors, tinnitus (ear ringing or buzzing)
- tingling sensations
- troubling thoughts
- visual hallucinations / illusions
- vivid dreams
- speech or visual changes
- worsened depression 
IMAGINE BEING FREE OF MIRTAZAPINE DEPENDENCY
✔ Proven Program completed In-Home with Expert Guidance
✔ Slowly Wean Off Mirtazapine
✔ All-Natural Nutraceuticals to help ease symptoms and make Mirtazapine Withdrawal easier*
✔ Professional information on interactions
✔ Free Mentoring on our 24/7 private Discussion Board
✔ Free Assessment Upon Starting our Program (a $400 value)
Enter Discount Code BenzoFree for FREE Ground Shipping on your Withdrawal Program (USA & Canada Only)
MIRTAZAPINE WITHDRAWAL TIMELINE
Mirtazapine withdrawal may be different for each person and while there is no exact timeline, the symptoms generally begin within 24 hours or missing or lowering a dose of Mirtazapine.  Clinical reports describe withdrawal symptoms of panic, anxiety, restlessness, irritability, insomnia, hypomania, nausea and vomiting after a decrease or discontinuation of Mirtazapine. Studies have shown that Mirtazapine withdrawal symptoms and syndromes may occur during and despite tapering off Mirtazapine slowly.
Point of Return has implemented a powerful, proven, holistic approach to Mirtazapine Withdrawal over the past 17 years. We have found that utilizing calming supplements, eliminating any interaction item combined with a gradual taper provides the best chance to successfully taper off Mirtazapine.*
MIRTAZAPINE WITHDRAWAL SUCCESS STORIES
This experience has left me humbled and oh so grateful. Please let Point of Return work for you. They will provide the tools you need to succeed. More...
Vicky (Mirtazapine Withdrawal Success Story)
I owe it all to you, and everyone else at Point of Return. I am forever grateful, and I will never stop telling people about Point of Return. More...
Trudee (Mirtazapine Withdrawal Success Story)
I cannot say enough good things about the entire POR team. I will be forever grateful. Thank you from the bottom of my heart. More...
Mark (Mirtazapine Withdrawal Success Story)
MIRTAZAPINE SIDE EFFECTS AND ADVERSE REACTIONS
MIRTAZAPINE SIDE EFFECTS MAY INCLUDE:
Abdominal pain, Chills, Fever, Face Edema, Ulcer, Neck rigidity, Neck pain, Chest pain, Hypertension, Angina, Migraine, Goiter, Hypothyroidism, Thirst or dehydration, Weight loss, Abnormal healing, Diabetes, Arthritis or bursitis, Anxiety, Agitation, Twitching, Hostility, Reflexes increased, Convulsions, Sinusitis, Cough increased, Rash, Acne, Urinary retention
MIRTAZAPINE ADVERSE REACTIONS MAY INCLUDE: per PDR
Severe: cholecystitis, bronchospasm, bradycardia, myocardial infarction, exfoliative dermatitis, ocular hypertension, keratoconjunctivitis, hearing loss, muscle paralysis, seizures, GI obstruction, pancreatitis, cirrhosis, tendon rupture, bone fractures, asphyxia, pneumothorax, pulmonary embolism, heart failure, pancytopenia, serotonin syndrome, suicidal ideation, habdomyolysis, ventricular fibrillation, torsade de pointes, agranulocytosis, diabetic ketoacidosis, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis
Moderate: hypercholesterolemia, constipation, hypertriglyceridemia, confusion, elevated hepatic enzymes, peripheral edema, hyperreflexia, delirium, dysarthria, ataxia, migraine, mania, hostility, hallucinations, depression, euphoria, dyskinesia, dystonic reaction, stomatitis, colitis, glossitis, dyspnea, angina, hypotension, dehydration, dysuria, hematuria, cystitis, urinary incontinence, impotence (erectile dysfunction), vaginitis, nephrolithiasis, urinary retention, hyperacusis, conjunctivitis, edema, aphasia, nystagmus, myoclonia, hypotonia, gastritis, oral ulceration, candidiasis, bone pain, phlebitis, lymphadenopathy, lymphocytosis, thrombocytopenia, leukopenia, anemia, gout, hyponatremia, diabetes mellitus, skin ulcer, ejaculation dysfunction, goiter, hypothyroidism, blepharitis, withdrawal, amnesia, myasthenia, peripheral vasodilation, hypertension, orthostatic hypotension, QT prolongation, neutropenia, hyperglycemia, bullous rash
Mild: drowsiness, weight gain, xerostomia, appetite stimulation, asthenia, dizziness, influenza, abnormal dreams, tremor, back pain, myalgia, increased urinary frequency, libido increase, emotional lability, paranoia, eructation, weight loss, nausea, epistaxis, syncope, fever, acne vulgaris, alopecia, xerosis, mastalgia, amenorrhea , dysmenorrhea, leukorrhea, otalgia, ocular pain, chills, headache, diplopia, tongue discoloration, hypersalivation, laryngitis, hiccups, petechiae, seborrhea, urticaria, polyuria, urinary urgency, breast enlargement, menorrhagia, parosmia, dysgeusia, paresthesias, hyperkinesis, hypoesthesia, vertigo, agitation, anxiety, abdominal pain, vomiting, anorexia, arthralgia, sinusitis, cough, polydipsia, rash, pruritus, photosensitivity, malaise, restlessness, infection
MIRTAZAPINE BOXED WARNINGS: per PDR:
Children, suicidal ideation
Mirtazapine is not FDA-approved for the treatment of depression in adolescents or children; safety and efficacy have not been established. Two manufacturer-sponsored, randomized, double-blind, placebo-controlled clinical trials in pediatric patients 7 to 18 years of age with major depressive disorder (n = 259) failed to demonstrate significant differences between mirtazapine and placebo with regard to the primary endpoint and all secondary endpoints. In October 2004, the FDA directed manufacturers of all antidepressants to add a boxed warning to their product labels detailing the risk of suicide in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4,400) lasting up to 16 weeks in pediatric patients with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants. The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment with antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in pediatrics or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or during dose changes. It is unknown if the suicidality risk in children or young adults extends to longer-term therapy. The possibility of a suicide attempt is inherent in patients with depressive symptoms, whether these occur in primary depression or in association with another primary disorder. All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment should be closely monitored during treatment with mirtazapine. In patients who exhibit worsening of depression or suicidality, a decision should be made to change or discontinue treatment. If discontinuing, the medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. All antidepressants should be prescribed in the smallest quantity consistent with good patient management to reduce the risk of overdose.
MIRTAZAPINE TECHNICAL DATA AND REFERENCES
Nervous System: frequent: hypesthesia, apathy, depression, hypokinesia, vertigo, twitching, agitation, anxiety, amnesia, hyperkinesia, paresthesia; infrequent: ataxia, delirium, delusions, depersonalization, dyskinesia, extrapyramidal syndrome, libido increased, coordination abnormal, dysarthria, hallucinations, manic reaction, neurosis, dystonia, hostility, reflexes increased, emotional lability, euphoria, paranoid reaction; rare: aphasia, nystagmus, akathisia, stupor, dementia, diplopia, drug dependence, paralysis, grand mal convulsion, hypotonia, myoclonus, psychotic depression, withdrawal syndrome
*While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.
*The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.
*The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized with Your physician to help you with your drug withdrawal process and with his or her consent throughout.
*This program is not meant to cure or prevent any disease or illness.
*Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..